These observations suggest that targeting Gdpd3 or other enzymes that are involved in lysophospholipid metabolism can contribute in reducing CML disease relapse (110). This evidence concerns the gene GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive.